Epigenetic CRISPR screens identify Npm1 as a therapeutic vulnerability in non-small cell lung cancer

Despite advancements in treatment options, the overall cure and survival rates for non-small cell lung cancers (NSCLC) remain low. While small-molecule inhibitors of epigenetic regulators have recently emerged as promising cancer therapeutics, their application in patients with NSCLC is limited. To...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Res
Päätekijät: Li, Fei, Ng, Wai-Lung, Luster, Troy A., Hu, Hai, Sviderskiy, Vladislav O., Dowling, Catríona M., Hollinshead, Kate E.R., Zouitine, Paula, Zhang, Hua, Huang, Qingyuan, Ranieri, Michela, Wang, Wei, Fang, Zhaoyuan, Chen, Ting, Deng, Jiehui, Zhao, Kai, So, Hon-Cheong, Khodadadi-Jamayran, Alireza, Xu, Mousheng, Karatza, Angeliki, Pyon, Val, Li, Shuai, Pan, Yuanwang, Labbe, Kristen, Almonte, Christina, Poirier, John T., Miller, George, Possemato, Richard, Qi, Jun, Wong, Kwok-Kin
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2020
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7493834/
https://ncbi.nlm.nih.gov/pubmed/32646968
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-19-3782
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia